Antula Acquisition Expands Meda's OTC Portfolio, Marketing Expertise
This article was originally published in The Tan Sheet
Executive Summary
Meda's acquisition of fast-growing Swedish OTC firm Antula Healthcare brings on board "proven" marketing expertise to boost existing product sales, a well-established nonprescription drug portfolio and a prolific pipeline for long-term growth.
You may also be interested in...
In Brief: Vitamix Expands, No “Probiotic” In E.U. Ads, Mylan Misses On Meda, Akorn Hits On VersaPharm
Vitamix triples manufacturing space; using ‘probiotic’ not allowed in E.U.; Meda rejects Mylan bids; Akorn acquires VersaPharm; La. blocks DXM sales to minors; and more news In Brief.
In Brief: Vitamix Expands, No “Probiotic” In E.U. Ads, Mylan Misses On Meda, Akorn Hits On VersaPharm
Vitamix triples manufacturing space; using ‘probiotic’ not allowed in E.U.; Meda rejects Mylan bids; Akorn acquires VersaPharm; La. blocks DXM sales to minors; and more news In Brief.
Meda Pumps Up Iron With Feosol Relaunch, Revamps Neglected OTCs
Meda Consumer Healthcare is relaunching the Feosol iron supplement brand with three SKUs and aims to become the clear No. 1 brand in the category. Meda’s Swedish parent company prioritizes OTC growth through brand acquisitions and increased marketing resources.